Aktienanalyse zu ALX Oncology Holdings Inc (ALXO)ALXOALX Oncology Holdings Inc

ALX Oncology Holdings Inc. is a clinical-stage biotechnology company advancing a pipeline of therapies designed to treat cancer and extend patients’ lives. The Company's lead product candidate, evorpacept, is a CD47 blocking therapeutic that combines a high-affinity CD47 binding domain with an inactivated, proprietary Fc domain. It is engaged in focusing on combining evorpacept with anti-cancer antibodies, antibody drug conjugate (ADCs), and PD-1/PD-L1 immune checkpoint inhibitors. Evorpacept is being evaluated across multiple ongoing clinical trials in a range of cancer indications. Its second product candidate is ALX2004, an epidermal growth factor receptor (EGFR)-targeted ADC. ALX2004 comprises an affinity-tuned EGFR antibody backbone engineered for optimal activity as an ADC, a proprietary topoisomerase I inhibitor payload with enhanced bystander effect, and a linker with enhanced stability. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

ALX Oncology Holdings Inc is a good buy right now due to its recent price increase of 21.24% over the last five days, indicating strong momentum. The current price of $1.37 is well below its 52-week high of $2.66, suggesting potential for growth. Additionally, the company has sufficient cash reserves of $153.4 million to fund operations through mid-2028, which provides a buffer against financial instability. However, the main risk is the negative earnings trend, with a projected EPS of -0.14 for the upcoming earnings report on November 6, 2026.